| Acronym | Definition |
|---|---|
| ACLF | Acute on Chronic Liver Failure |
| AI | Artificia intelligence |
| ALTAI | the Assessment List for Trustworthy Artificial Intelligence |
| AP-HP | Assistance Publique-Hôpitaux de Paris |
| ARFI | Acoustic radiation force impulse |
| CA | Consortium Agreement |
| CAGR | Compound Annual Growth Rate |
| CBM | Centre-based models |
| CDM | Common data model |
| CDSS | Clinical decision support system |
| CLD | Chronic liver disease |
| CE mark | Conformité Européenne mark |
| CFD | Computational Fluid Dynamics |
| CPMG | Carr-Purcell-Meiboom-Gill |
| CPU | Central Processing Unit |
| CT | Computed Tomography |
| CVD | Cardiovascular disease |
| DCM | Deformable Cell Model |
| DL | Deep learning |
| DM | Diabetes Mellitus |
| DMP | Data Management Plan |
| DPO | Data Protection Officer |
| eCRF | Electronic Case Report Form |
| EASL | European Association for the Study of the Liver |
| EC | European Commission |
| ECM | Extra-Cellular Matrix |
| ECOG | Eastern Cooperative Oncology Group |
| EHDS | European Health Data Space |
| EHR | Electronic Health Report |
| EIA | Ethics Impact Assessment |
| ETL | Extract-Transform-Load |
| FAIR | Findability, Accessibility, Interoperability and Reusability |
| FL | Federated Learning |
| FDA | Food and Drug Administration |
| GA | Grant Agreement |
| GDPR | The General Data Protection Regulation |
| GPU | Graphics Processing Unit |
| HBV | Hepatitis B virus |
| HCC | Hepatocellular carcinomas |
| HCV | Hepatitis C virus |
| HeTran-BL | Hemodynamics and transport at whole body level |
| HeTran-OL | Hemodynamics and transport at the organ level |
| HeTran-TL | Hemodynamics and transport at the tissue level |
| HF | Heart Failure |
| HGF | Hepatocyte growth factor |
| HIS | Hospital Information System |
| HIV | Human immunodeficiency virus |
| HPC | High Performance Cloud |
| HRS-1 | Hepatorenal syndrome type 1 |
| HSC | Hepatic stellate cells |
| HTA | Health technology assessment |
| HVPG | Hepatic venous pressure gradient |
| ICI | Immune checkpoint inhibitor(s) |
| IL | Interleukin |
| INF | Interferon |
| IP | Intellectual Property |
| IT | Information Technology |
| JUH | Jena University Hospital |
| KER | Key exploitable results |
| KOL | Key opinion leaders |
| KRCO | Key Relevant Clinical Outputs |
| L-VT | Liver virtual twin |
| MACE | Major Adverse Cardiac Events |
| MASLD | Metabolic-associated fatty liver disease |
| MDR | Medical Device Regulation |
| MELD | Model for End-Stage Liver Disease |
| ML | Machine Learning |
| MR-elastography | Magnetic Resonance elastography |
| MRI | Magnetic Resonance Imaging |
| MVP | Minimum viable product |
| My-VT | heart Myocardial Virtual Twin |
| NAFLD | Nonalcoholic fatty liver disease |
| NASH | Nonalcoholic steatohepatitis |
| NLP | Natural language processing |
| NMR | Nuclear Magnetic Resonance |
| ODE | Ordinary Differential Equations |
| OHIF | Open Health Imaging Foundation |
| ORE | Open research europe |
| PACS | Picture Archiving and Communication System |
| PCB | Project coordination board |
| PCSB | Project Clinical Study Board |
| PDE | Partial Differential Equations |
| PHES | Psychometric Hepatic Encephalopathy Score |
| POC | Proof of concept |
| SBML | Systems Biology Markup Language |
| SCORE | Systemic Coronary Risk Estimation |
| SME | Small and middle enterprises |
| SSH | Social Sciences and Humanities |
| SOTA | State-of-the-art |
| SW | Software |
| T2DM | Type 2 Diabetes Mellitus |
| TACE | Trans-arterial chemoembolization |
| TGF | Transforming growth factor |
| TKI | Tyrosine kinase inhibitors |
| TIPS | Transjugular intrahepatic portosystemic shunt |
| UKHD | Universitat Klinikum Heidelberg |
| VCTE | Vibration controlled transient elastography |
| VT | Virtual Twin |
| VVUQ | Verification, Validation, and Uncertainty Quantification |